Illumina Is Using Acquisitions to Challenge Roche in Fast-growing Market for Gene-based Clinical Pathology Laboratory Testing

Hot competition for genetic testing market share is a signal to medical laboratories to ramp up their molecular and genetic testing capabilities Financial analysts see something of an “old west” style shootout on the horizon for genetic testing in the clinical laboratory testing market. Market leaders in next-generation gene sequencing are prepared to use acquisitions to build dominant shares in a gene testing market that experts say could hit $25 billion by 2022. Reporters at Bloomberg...

Illumina Intends to Migrate Array Technology to Clinical Laboratories

Firm will submit cytogenetic testing system to FDA using pre-IDE process High-throughput microarray technology used in cytogenetics research may soon have an FDA-cleared product for use by clinical pathology laboratories. Array-based comparative genomic hybridization can perform the equivalent of hundreds or even thousands of fluorescence in situ hybridization (FISH)  experiments in one array. This technology has become the preferred method for molecular cytogenetics research. Recent advances...
;